Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-08-02

AUTHORS

Rosarin Sruamsiri, Hideto Kameda, Jörg Mahlich

ABSTRACT

OBJECTIVE: The study assessed persistence rates of biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis in Japan and compared resource utilization and treatment costs between persistence and non-persistence groups. METHODS: Data were extracted from a Japanese claims database between 2009 and 2015. bDMARD-naïve patients were identified and included in the final analysis. Survival analysis was used to estimate 1-year persistence rates for current bDMARDs. Propensity score matching was applied to control for potential treatment selection bias. Resource utilization and healthcare costs were calculated 1 year before and after initiation of bDMARDs and compared between persistence and non-persistence groups. RESULTS: A total of 6153 bDMARD-naïve patients were identified and the overall 1-year persistence rate was 85% (95% CI 84-86). Overall, 1-year outpatient visits increased from 10 at baseline to 16 after bDMARD treatment, while the number of hospital admissions declined from 3.3 to 1.6. The non-persistence group had a larger increase in outpatient visits after bDMARD initiation compared with the persistence group (8-16 vs. 10-16, respectively) and a smaller decrease in hospital admissions (3.1-1.9 vs. 3.5-1.4, respectively). Persistence was associated with a reduction in total healthcare costs of US$760. CONCLUSIONS: Japanese bDMARD-naïve patients with RA have a high persistence rate with those treatments. The reduction in medication costs in non-persistent patients is offset by higher hospitalization costs, making non-persistence more expensive. More... »

PAGES

169-179

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40801-018-0139-8

DOI

http://dx.doi.org/10.1007/s40801-018-0139-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1105964979

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30073580


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Center of Pharmaceutical Outcomes Research, Naresuan University, Muang Phitsanulok, Thailand", 
          "id": "http://www.grid.ac/institutes/grid.412029.c", 
          "name": [
            "Health Economics, Janssen Pharmaceutical KK, 5-2, Nishi-kanda 3-chome Chiyoda-ku, 101-0065 Tokyo, Japan", 
            "Center of Pharmaceutical Outcomes Research, Naresuan University, Muang Phitsanulok, Thailand"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sruamsiri", 
        "givenName": "Rosarin", 
        "id": "sg:person.01012072225.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012072225.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Rheumatology, Toho University Ohashi Medical Center, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.470115.6", 
          "name": [
            "Division of Rheumatology, Toho University Ohashi Medical Center, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kameda", 
        "givenName": "Hideto", 
        "id": "sg:person.0656055364.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656055364.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "D\u00fcsseldorf Institute for Competition Economics (DICE), University of D\u00fcsseldorf, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Health Economics, Janssen Pharmaceutical KK, 5-2, Nishi-kanda 3-chome Chiyoda-ku, 101-0065 Tokyo, Japan", 
            "D\u00fcsseldorf Institute for Competition Economics (DICE), University of D\u00fcsseldorf, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mahlich", 
        "givenName": "J\u00f6rg", 
        "id": "sg:person.0103224776.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0103224776.88"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10916-008-9220-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047808293", 
          "https://doi.org/10.1007/s10916-008-9220-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40261-017-0517-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084038490", 
          "https://doi.org/10.1007/s40261-017-0517-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12895-018-0074-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105474392", 
          "https://doi.org/10.1186/s12895-018-0074-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-200623030-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040859747", 
          "https://doi.org/10.2165/00002512-200623030-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13561-014-0032-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002603952", 
          "https://doi.org/10.1186/s13561-014-0032-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/ar2084", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028965775", 
          "https://doi.org/10.1186/ar2084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40744-018-0096-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101165205", 
          "https://doi.org/10.1007/s40744-018-0096-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00296-016-3423-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000217293", 
          "https://doi.org/10.1007/s00296-016-3423-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-08-02", 
    "datePublishedReg": "2018-08-02", 
    "description": "OBJECTIVE: The study assessed persistence rates of biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis in Japan and compared resource utilization and treatment costs between persistence and non-persistence groups.\nMETHODS: Data were extracted from a Japanese claims database between 2009 and 2015. bDMARD-na\u00efve patients were identified and included in the final analysis. Survival analysis was used to estimate 1-year persistence rates for current bDMARDs. Propensity score matching was applied to control for potential treatment selection bias. Resource utilization and healthcare costs were calculated 1\u00a0year before and after initiation of bDMARDs and compared between persistence and non-persistence groups.\nRESULTS: A total of 6153 bDMARD-na\u00efve patients were identified and the overall 1-year persistence rate was 85% (95% CI 84-86). Overall, 1-year outpatient visits increased from 10 at baseline to 16 after bDMARD treatment, while the number of hospital admissions declined from 3.3 to 1.6. The non-persistence group had a larger increase in outpatient visits after bDMARD initiation compared with the persistence group (8-16 vs. 10-16, respectively) and a smaller decrease in hospital admissions (3.1-1.9 vs. 3.5-1.4, respectively). Persistence was associated with a reduction in total healthcare costs of US$760.\nCONCLUSIONS: Japanese bDMARD-na\u00efve patients with RA have a high persistence rate with those treatments. The reduction in medication costs in non-persistent patients is offset by higher hospitalization costs, making non-persistence more expensive.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40801-018-0139-8", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1051855", 
        "issn": [
          "2199-1154", 
          "2198-9788"
        ], 
        "name": "Drugs - Real World Outcomes", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "keywords": [
      "biological disease-modifying antirheumatic drugs", 
      "bDMARD-na\u00efve patients", 
      "antirheumatic drugs", 
      "persistence rates", 
      "hospital admission", 
      "outpatient visits", 
      "healthcare costs", 
      "potential treatment selection bias", 
      "disease-modifying antirheumatic drugs", 
      "non-persistent patients", 
      "total healthcare costs", 
      "higher hospitalization costs", 
      "Japanese claims database", 
      "treatment selection bias", 
      "associated resource utilization", 
      "higher persistence rates", 
      "bDMARD treatment", 
      "rheumatoid arthritis", 
      "medication costs", 
      "claims database", 
      "hospitalization costs", 
      "patients", 
      "survival analysis", 
      "propensity score", 
      "biological disease", 
      "final analysis", 
      "treatment costs", 
      "persistence group", 
      "admission", 
      "treatment", 
      "selection bias", 
      "visits", 
      "drugs", 
      "resource utilization", 
      "group", 
      "small decrease", 
      "arthritis", 
      "initiation", 
      "disease", 
      "baseline", 
      "persistence", 
      "rate", 
      "large increase", 
      "scores", 
      "total", 
      "reduction", 
      "years", 
      "RA", 
      "utilization", 
      "decrease", 
      "study", 
      "database", 
      "increase", 
      "analysis", 
      "data", 
      "number", 
      "bias", 
      "Japan", 
      "cost", 
      "non-persistence groups", 
      "current bDMARDs", 
      "initiation of bDMARDs", 
      "Japanese bDMARD-na\u00efve patients"
    ], 
    "name": "Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs", 
    "pagination": "169-179", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1105964979"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40801-018-0139-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30073580"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40801-018-0139-8", 
      "https://app.dimensions.ai/details/publication/pub.1105964979"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_778.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40801-018-0139-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0139-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0139-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0139-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0139-8'


 

This table displays all metadata directly associated to this object as RDF triples.

179 TRIPLES      22 PREDICATES      97 URIs      81 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40801-018-0139-8 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N8147fb11bc8c4626ada1f20ae9d93a49
4 schema:citation sg:pub.10.1007/s00296-016-3423-5
5 sg:pub.10.1007/s10916-008-9220-2
6 sg:pub.10.1007/s40261-017-0517-0
7 sg:pub.10.1007/s40744-018-0096-4
8 sg:pub.10.1186/ar2084
9 sg:pub.10.1186/s12895-018-0074-0
10 sg:pub.10.1186/s13561-014-0032-4
11 sg:pub.10.2165/00002512-200623030-00002
12 schema:datePublished 2018-08-02
13 schema:datePublishedReg 2018-08-02
14 schema:description OBJECTIVE: The study assessed persistence rates of biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis in Japan and compared resource utilization and treatment costs between persistence and non-persistence groups. METHODS: Data were extracted from a Japanese claims database between 2009 and 2015. bDMARD-naïve patients were identified and included in the final analysis. Survival analysis was used to estimate 1-year persistence rates for current bDMARDs. Propensity score matching was applied to control for potential treatment selection bias. Resource utilization and healthcare costs were calculated 1 year before and after initiation of bDMARDs and compared between persistence and non-persistence groups. RESULTS: A total of 6153 bDMARD-naïve patients were identified and the overall 1-year persistence rate was 85% (95% CI 84-86). Overall, 1-year outpatient visits increased from 10 at baseline to 16 after bDMARD treatment, while the number of hospital admissions declined from 3.3 to 1.6. The non-persistence group had a larger increase in outpatient visits after bDMARD initiation compared with the persistence group (8-16 vs. 10-16, respectively) and a smaller decrease in hospital admissions (3.1-1.9 vs. 3.5-1.4, respectively). Persistence was associated with a reduction in total healthcare costs of US$760. CONCLUSIONS: Japanese bDMARD-naïve patients with RA have a high persistence rate with those treatments. The reduction in medication costs in non-persistent patients is offset by higher hospitalization costs, making non-persistence more expensive.
15 schema:genre article
16 schema:inLanguage en
17 schema:isAccessibleForFree true
18 schema:isPartOf N7bb953f1245e4bf18b5d7b711efdce0d
19 Nc0bccbf966f343faa090cd7808cc83cd
20 sg:journal.1051855
21 schema:keywords Japan
22 Japanese bDMARD-naïve patients
23 Japanese claims database
24 RA
25 admission
26 analysis
27 antirheumatic drugs
28 arthritis
29 associated resource utilization
30 bDMARD treatment
31 bDMARD-naïve patients
32 baseline
33 bias
34 biological disease
35 biological disease-modifying antirheumatic drugs
36 claims database
37 cost
38 current bDMARDs
39 data
40 database
41 decrease
42 disease
43 disease-modifying antirheumatic drugs
44 drugs
45 final analysis
46 group
47 healthcare costs
48 higher hospitalization costs
49 higher persistence rates
50 hospital admission
51 hospitalization costs
52 increase
53 initiation
54 initiation of bDMARDs
55 large increase
56 medication costs
57 non-persistence groups
58 non-persistent patients
59 number
60 outpatient visits
61 patients
62 persistence
63 persistence group
64 persistence rates
65 potential treatment selection bias
66 propensity score
67 rate
68 reduction
69 resource utilization
70 rheumatoid arthritis
71 scores
72 selection bias
73 small decrease
74 study
75 survival analysis
76 total
77 total healthcare costs
78 treatment
79 treatment costs
80 treatment selection bias
81 utilization
82 visits
83 years
84 schema:name Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs
85 schema:pagination 169-179
86 schema:productId N5d245c71dd9449ae96bbbb4ae69e529b
87 Neca835a981f24bd99021308b1dd71e80
88 Nf7e1ecdf4c634e15b24069f18ee987b9
89 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105964979
90 https://doi.org/10.1007/s40801-018-0139-8
91 schema:sdDatePublished 2021-12-01T19:41
92 schema:sdLicense https://scigraph.springernature.com/explorer/license/
93 schema:sdPublisher N0e244a0ab4374ca1b837c5e55e972bfc
94 schema:url https://doi.org/10.1007/s40801-018-0139-8
95 sgo:license sg:explorer/license/
96 sgo:sdDataset articles
97 rdf:type schema:ScholarlyArticle
98 N0b9077988ab54cbcb0123aa11fdb0c62 rdf:first sg:person.0103224776.88
99 rdf:rest rdf:nil
100 N0dae1357118946259fba416549ed570a rdf:first sg:person.0656055364.47
101 rdf:rest N0b9077988ab54cbcb0123aa11fdb0c62
102 N0e244a0ab4374ca1b837c5e55e972bfc schema:name Springer Nature - SN SciGraph project
103 rdf:type schema:Organization
104 N5d245c71dd9449ae96bbbb4ae69e529b schema:name dimensions_id
105 schema:value pub.1105964979
106 rdf:type schema:PropertyValue
107 N7bb953f1245e4bf18b5d7b711efdce0d schema:volumeNumber 5
108 rdf:type schema:PublicationVolume
109 N8147fb11bc8c4626ada1f20ae9d93a49 rdf:first sg:person.01012072225.20
110 rdf:rest N0dae1357118946259fba416549ed570a
111 Nc0bccbf966f343faa090cd7808cc83cd schema:issueNumber 3
112 rdf:type schema:PublicationIssue
113 Neca835a981f24bd99021308b1dd71e80 schema:name pubmed_id
114 schema:value 30073580
115 rdf:type schema:PropertyValue
116 Nf7e1ecdf4c634e15b24069f18ee987b9 schema:name doi
117 schema:value 10.1007/s40801-018-0139-8
118 rdf:type schema:PropertyValue
119 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
120 schema:name Medical and Health Sciences
121 rdf:type schema:DefinedTerm
122 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
123 schema:name Clinical Sciences
124 rdf:type schema:DefinedTerm
125 sg:journal.1051855 schema:issn 2198-9788
126 2199-1154
127 schema:name Drugs - Real World Outcomes
128 schema:publisher Springer Nature
129 rdf:type schema:Periodical
130 sg:person.01012072225.20 schema:affiliation grid-institutes:grid.412029.c
131 schema:familyName Sruamsiri
132 schema:givenName Rosarin
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012072225.20
134 rdf:type schema:Person
135 sg:person.0103224776.88 schema:affiliation grid-institutes:grid.411327.2
136 schema:familyName Mahlich
137 schema:givenName Jörg
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0103224776.88
139 rdf:type schema:Person
140 sg:person.0656055364.47 schema:affiliation grid-institutes:grid.470115.6
141 schema:familyName Kameda
142 schema:givenName Hideto
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656055364.47
144 rdf:type schema:Person
145 sg:pub.10.1007/s00296-016-3423-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000217293
146 https://doi.org/10.1007/s00296-016-3423-5
147 rdf:type schema:CreativeWork
148 sg:pub.10.1007/s10916-008-9220-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047808293
149 https://doi.org/10.1007/s10916-008-9220-2
150 rdf:type schema:CreativeWork
151 sg:pub.10.1007/s40261-017-0517-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084038490
152 https://doi.org/10.1007/s40261-017-0517-0
153 rdf:type schema:CreativeWork
154 sg:pub.10.1007/s40744-018-0096-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101165205
155 https://doi.org/10.1007/s40744-018-0096-4
156 rdf:type schema:CreativeWork
157 sg:pub.10.1186/ar2084 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028965775
158 https://doi.org/10.1186/ar2084
159 rdf:type schema:CreativeWork
160 sg:pub.10.1186/s12895-018-0074-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105474392
161 https://doi.org/10.1186/s12895-018-0074-0
162 rdf:type schema:CreativeWork
163 sg:pub.10.1186/s13561-014-0032-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002603952
164 https://doi.org/10.1186/s13561-014-0032-4
165 rdf:type schema:CreativeWork
166 sg:pub.10.2165/00002512-200623030-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040859747
167 https://doi.org/10.2165/00002512-200623030-00002
168 rdf:type schema:CreativeWork
169 grid-institutes:grid.411327.2 schema:alternateName Düsseldorf Institute for Competition Economics (DICE), University of Düsseldorf, Düsseldorf, Germany
170 schema:name Düsseldorf Institute for Competition Economics (DICE), University of Düsseldorf, Düsseldorf, Germany
171 Health Economics, Janssen Pharmaceutical KK, 5-2, Nishi-kanda 3-chome Chiyoda-ku, 101-0065 Tokyo, Japan
172 rdf:type schema:Organization
173 grid-institutes:grid.412029.c schema:alternateName Center of Pharmaceutical Outcomes Research, Naresuan University, Muang Phitsanulok, Thailand
174 schema:name Center of Pharmaceutical Outcomes Research, Naresuan University, Muang Phitsanulok, Thailand
175 Health Economics, Janssen Pharmaceutical KK, 5-2, Nishi-kanda 3-chome Chiyoda-ku, 101-0065 Tokyo, Japan
176 rdf:type schema:Organization
177 grid-institutes:grid.470115.6 schema:alternateName Division of Rheumatology, Toho University Ohashi Medical Center, Tokyo, Japan
178 schema:name Division of Rheumatology, Toho University Ohashi Medical Center, Tokyo, Japan
179 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...